Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926353 | 0.86 | ADRA1A (0.51) | HTR1ADRD2ADRA1A | |
| SCHEMBL6926357 | 0.85 | DRD2 (0.52) | HTR1ADRD2DRD3 | |
| SCHEMBL6926540 | 0.83 | MEN1 (0.45) | MEN1KMT2AHTR1AHTR7DRD2 | |
| SCHEMBL6927068 | 0.83 | DRD2 (0.41) | MEN1KMT2AHTR7DRD2 | |
| SCHEMBL6925552 | 0.82 | DRD2 (0.50) | MEN1KMT2AHTR1AHTR7DRD2 | |
| SCHEMBL5592219 | 0.77 | HTR7 (0.64) | MEN1KMT2AHTR1AHTR7DRD2 | |
| SCHEMBL8148403 | 0.77 | HTR1A (0.57) | HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL5592239 | 0.76 | HTR7 (0.62) | MEN1KMT2AHTR1AHTR7DRD2 | |
| SCHEMBL4522960 | 0.76 | HTR1A (0.61) | MEN1KMT2AHTR1AHTR7DRD2 | |
| SCHEMBL5424281 | 0.75 | HTR1A (0.56) | MEN1KMT2AHTR1AHTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | H. LUNDBECK A/S (DE) | 2003-06-26 | — | — | US | disclosed |
| US-6514993-B1 | Useful in the treatment of certain psychic and neurologic disorders | H. LUNDBECK A/S (DK) | 2003-02-04 | — | — | US | disclosed |
| EP-0770066-B1 | SEROTONIN 5-HT 1A AND DOPAMIN D2 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2000-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | HTR5A, HTR2C, HTR1D | MEN1 3854/4885KMT2A 2068/4885HTR1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.